© Reuters. FILE PHOTO: The logo for Biohaven Pharmaceutical Holding Company is displayed on a screen during the company’s IPO on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 4, 2017. REUTERS/Brendan McDermid
(Reuters) – Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed to meet the main goal and secondary goals of a mid-to-late stage study.
The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc (NYSE:), which plans to spin off its non-migraine drugs into a new publicly traded company.
Be the first to comment